Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurocritical Care
Erschienen in: Neurocritical Care 3/2013

01.06.2013 | Review Article

Hyponatremia and Brain Injury: Historical and Contemporary Perspectives

verfasst von: Matthew A. Kirkman, Angelique F. Albert, Ahmed Ibrahim, Doris Doberenz

Erschienen in: Neurocritical Care | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Hyponatremia is common in neurocritical care patients and is associated with significant morbidity and mortality. Despite decades of research into the syndrome of inappropriate antidiuretic hormone (SIADH) and cerebral salt wasting (CSW), their underlying pathophysiological mechanisms are still not fully understood. This paper reviews the history behind our understanding of hyponatremia in patients with neurologic injury, including the first reports of CSW and SIADH, and current and future challenges to diagnosis and management in this setting. Such challenges include distinguishing CSW, SIADH, and hypovolemic hyponatremia due to a normal pressure natriuresis from the administration of large volumes of fluids, and hyponatremia due to certain medications used in the neurocritical care population. Potential treatments for hyponatremia include mineralocorticoids and vasopressin 2 receptor antagonists, but further work is required to validate their usage. Ultimately, a greater understanding of the pathophysiological mechanisms underlining hyponatremia in neurocritical care patients remains our biggest obstacle to optimizing patient outcomes in this challenging population.
Literatur
1.
Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006;4:10.PubMedCrossRef
2.
Tisdall M, Crocker M, Watkiss J, Smith M. Disturbances of sodium in critically ill adult neurologic patients: a clinical review. J Neurosurg Anesthesiol. 2006;18(1):57–63.PubMedCrossRef
3.
Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist. 2003;9:290–300.PubMedCrossRef
4.
DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990;34(4):163–6.PubMed
5.
Bennani SL, Abouqal R, Zeggwagh AA, et al. Incidence, causes and prognostic factors of hyponatremia in intensive care. Rev Med Interne. 2003;24(4):224–9.PubMedCrossRef
6.
Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21(1):70–6.PubMedCrossRef
7.
Zada G, Liu CY, Fishback D, Singer PA, Weiss MH. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg. 2007;106(1):66–71.PubMedCrossRef
8.
Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30–5.PubMedCrossRef
9.
Sherlock M, O’Sullivan E, Agha A, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf). 2006;64(3):250–4.CrossRef
10.
Sata A, Hizuka N, Kawamata T, Hori T, Takano K. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. Neuroendocrinology. 2006;83(2):117–22.PubMedCrossRef
11.
Peruzzi WT, Shapiro BA, Meyer PR Jr, Krumlovsky F, Seo BW. Hyponatremia in acute spinal cord injury. Crit Care Med. 1994;22(2):252–8.PubMedCrossRef
12.
Kurokawa Y, Uede T, Ishiguro M, et al. Pathogenesis of hyponatremia following subarachnoid hemorrhage due to ruptured cerebral aneurysm. Surg Neurol. 1996;46(5):500–7; discussion 507–8.PubMedCrossRef
13.
Callewart CC, Minchew JT, Kanim LE, et al. Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in adult spinal surgery. Spine (Phila Pa 1976) 1994;19(15):1674–9.
14.
Diringer MN, Zazulia AR. Hyponatremia in neurologic patients: consequences and approaches to treatment. Neurologist. 2006;12:117–26.PubMedCrossRef
15.
Adrogue HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005;25:240–9.PubMedCrossRef
16.
Dellabarca C, Servilla KS, Hart B, Murata GH, Tzamaloukas AH. Osmotic myelinolysis following chronic hyponatremia corrected at an overall rate consistent with current recommendations. Int Urol Nephrol. 2005;37:171–3.PubMedCrossRef
17.
Cushny AR. The secretion of the urine. London: Longman’s Green & Co; 1926.
18.
Jungmann J, Meyer E. Experimentelle Untersuchungen ueber die Abhaengigkeit der Nierenfunktion vom Nervensystem. Archiv f Exp Path und Pharm. 1913;73:49.CrossRef
19.
Peters JP, Welt LG, Sims EA, Orloff J, Needham J. A salt-wasting syndrome associated with cerebral disease. Trans Assoc Am Physicians. 1950;63:57–64.PubMed
20.
Welt LG, Seldin DW, Nelson WP, German WJ, Peters JP. Role of the central nervous system in metabolism of electrolytes and water. AMA Arch Intern Med. 1952;90(3):355–78.PubMedCrossRef
21.
Kaplan SA, Rapoport S. Urinary excretion of sodium and chloride after splanchnicotomy; effect on the proximal tubule. Am J Physiol. 1951;164(1):175–81.PubMed
22.
23.
Schwartz WB, Bennett W, Curelop S, Bartter FC. Syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.PubMedCrossRef
24.
Schwartz WB, Tassel D, Bartter FC. Further observations on hyponatremia and renal sodium loss probably resulting from inappropriate secretion of antidiuretic hormone. N Engl J Med. 1960;262:743–8.PubMedCrossRef
25.
Leaf A, Bartter FC, Santos RF, Wrong O. Evidence in man that urinary electrolyte loss induced by pitressin is function of water retention. J Clin Invest. 1953;32:868–78.PubMedCrossRef
26.
Epstein FH, Levitin H. “Cerebral salt-wasting”: example of sustained inappropriate release of antidiuretic horone. J Clin Invest. 1959;38:1001.CrossRef
27.
Carter NW, Rector FC Jr, Seldin DW. Pathogenesis of persistent hyponatremia with water retention in cerebral disease. Clin Res. 1959;7:273.
28.
Carter NW, Rector FC Jr, Seldin DW. Hyponatremia in cerebral disease resulting from the inappropriate secretion of antidiuretic hormone. N Engl J Med. 1961;264:67–72.PubMedCrossRef
29.
Nelson PB, Seif SM, Maroon JC, Robinson AG. Hyponatremia in intracranial disease: perhaps not the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Neurosurg. 1981;55(6):938–41.PubMedCrossRef
30.
Oh MS, Carroll HJ. Cerebral salt-wasting syndrome. We need better proof of its existence. Nephron. 1999;82(2):110–4.PubMedCrossRef
31.
Betjes MG. Hyponatremia in acute brain disease: the cerebral salt wasting syndrome. Eur J Intern Med. 2002;13(1):9–14.PubMedCrossRef
32.
Wijdicks EF, Vermeulen M, ten Haaf JA, et al. Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm. Ann Neurol. 1985;18(2):211–6.PubMedCrossRef
33.
Sivakumar V, Rajshekhar V, Chandy MJ. Management of neurosurgical patients with hyponatremia and natriuresis. Neurosurgery. 1994;34(2):269–74.PubMedCrossRef
34.
Audibert G, Steinmann G, de Talance N, et al. Endocrine response after severe subarachnoid hemorrhage related to sodium and blood volume regulation. Anesth Analg. 2009;108(6):1922–8.PubMedCrossRef
35.
Doczi T, Bende J, Huszka E, Kiss J. Syndrome of inappropriate secretion of antidiuretic hormone after subarachnoid hemorrhage. Neurosurgery. 1981;9(4):394–7.PubMedCrossRef
36.
Sherlock M, O’Sullivan E, Agha A, et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. 2009;85:171–5.PubMedCrossRef
37.
Brimioulle S, Orellana-Jimenez C, Aminian A, Vincent JL. Hyponatremia in neurological patients: cerebral salt wasting versus inappropriate antidiuretic hormone secretion. Intensive Care Med. 2008;34(1):125–31.PubMedCrossRef
38.
Rahman M, Friedman WA. Hyponatremia in neurosurgical patients: clinical guidelines development. Neurosurgery. 2009;65:925–36.PubMedCrossRef
39.
Singh S, Bohn D, Carlotti AP, et al. Cerebral salt wasting: truths, fallacies, theories, and challenges. Crit Care Med. 2002;30(11):2575–9.PubMedCrossRef
40.
Shamiss A, Peleg E, Rosenthal T, Ezra D. The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers. Eur J Pharmacol. 1993;233(1):113–7.PubMedCrossRef
41.
Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab. 1997;82(2):457–60.PubMedCrossRef
42.
Kosaka H, Hirayama K, Yoda N, et al. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol. 2010;635(1–3):49–55.PubMedCrossRef
43.
Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol. 2008;19(2):194–6.PubMedCrossRef
44.
Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics. 2006;118(6):e1904–8.PubMedCrossRef
45.
Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med. 1987;83(5):905–8.PubMedCrossRef
46.
47.
Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990;113(2):155–9.PubMedCrossRef
48.
49.
Maesaka JK, Gupta S, Fishbane S. Cerebral salt-wasting syndrome: does it exist? Nephron. 1999;82(2):100–9.PubMedCrossRef
50.
Damaraju SC, Rajshekhar V, Chandy MJ. Validation study of a central venous pressure-based protocol for the management of neurosurgical patients with hyponatremia and natriuresis. Neurosurgery. 1997;40(2):312–6; discussion 316–7.PubMedCrossRef
51.
Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008;134(1):172–8.PubMedCrossRef
52.
Sakka SG, Reuter DA, Perel A. The transpulmonary thermodilution technique. J Clin Monit Comput. 2012;26(5):347–53.PubMedCrossRef
53.
Bennington S, Ferris P, Nirmalan M. Emerging trends in minimally invasive haemodynamic monitoring and optimization of fluid therapy. Eur J Anaesthesiol. 2009;26(11):893–905.CrossRef
54.
Sayama T, Inamura T, Matsushima T, et al. High incidence of hyponatremia in patients with ruptured anterior communicating artery aneurysms. Neurol Res. 2000;22(2):151–5.PubMed
55.
Qureshi AI, Suri MF, Sung GY, et al. Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;50(4):749–55; discussion 755–6.PubMedCrossRef
56.
Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol. 1990;27(1):106–8.PubMedCrossRef
57.
Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol. 1985;17(2):137–40.PubMedCrossRef
58.
Isotani E, Suzuki R, Tomita K, et al. Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke. 1994;25(11):2198–203.PubMedCrossRef
59.
Wijdicks EF, Ropper AH, Hunnicutt EJ, Richardson GS, Nathanson JA. Atrial natriuretic factor and salt wasting after aneurysmal subarachnoid hemorrhage. Stroke. 1991;22(12):1519–24.PubMedCrossRef
60.
Wijdicks EF, Schievink WI, Burnett JC Jr. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1997;87(2):275–80.PubMedCrossRef
61.
Espiner EA, Leikis R, Ferch RD, et al. The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf). 2002;56(5):629–35.CrossRef
62.
Diringer M, Ladenson PW, Stern BJ, Schleimer J, Hanley DF. Plasma atrial natriuretic factor and subarachnoid hemorrhage. Stroke. 1988;19(9):1119–24.PubMedCrossRef
63.
Nakagawa I, Kurokawa S, Nakase H. Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage—clinical significance of serum atrial natriuretic peptide. Acta Neurochir (Wien). 2010;152(12):2147–52.CrossRef
64.
Berendes E, Walter M, Cullen P, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997;349(9047):245–9.PubMedCrossRef
65.
Tomida M, Muraki M, Uemura K, Yamasaki K. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998;29(8):1584–7.PubMedCrossRef
66.
Sviri GE, Feinsod M, Soustiel JF. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage. Clinical and TCD correlations. Stroke. 2000;31(1):118–22.PubMedCrossRef
67.
McGirt MJ, Blessing R, Nimjee SM, et al. Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery. 2004;54(6):1369–73; discussion 1373–4.PubMedCrossRef
68.
Tung PP, Olmsted E, Kopelnik A, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid haemorrhage. Stroke. 2005;36(7):1567–9.PubMedCrossRef
69.
Inoha S, Inamura T, Nakamizo A, et al. Fluid loading in rats increases serum brain natriuretic peptide concentration. Neurol Res. 2001;23(1):93–5.PubMedCrossRef
70.
Powner DJ, Hergenroeder GW, Awili M, Atik MA, Robertson C. Hyponatremia and comparison of NT-pro-BNP concentrations in blood samples from jugular bulb and arterial sites after traumatic brain injury in adults: a pilot study. Neurocrit Care. 2007;7(2):119–23.PubMedCrossRef
71.
Juul R, Edvinsson L, Ekman R, et al. Atrial natriuretic peptide-LI following subarachnoid haemorrhage in man. Acta Neurochir (Wien). 1990;106(1–2):18–23.CrossRef
72.
Oropello JM, Weiner L, Benjamin E. Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? No. Crit Care Clin. 1996;12(3):709–30.PubMedCrossRef
73.
Clifton GL, Ziegler MG, Grossman RG. Circulating catecholamines and sympathetic activity after head injury. Neurosurgery. 1981;8(1):10–4.PubMedCrossRef
74.
Israel A, Torres M, Cierco M, Barbella Y. Further evidence for a dopaminergic involvement in the renal action of centrally administered atrial natriuretic peptide in rats. Brain Res Bull. 1991;27(5):739–42.PubMedCrossRef
75.
Aperia AC. Renal dopamine system and salt balance. Am J Kidney Dis. 1998; 31:xlii–v.
76.
Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49(3):605–6.
77.
Muench E, Horn P, Bauhuf C, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35(8):1844–51.PubMedCrossRef
78.
Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211–40.PubMedCrossRef
79.
Cole CD, Gottfried ON, Liu JK, Couldwell WT. Hyponatremia in the neurosurgical patient: diagnosis and management. Neurosurg Focus. 2004;16(4):E9.PubMedCrossRef
80.
Mount DB. Fluid and Electrolyte Disturbances. In: Longo DL et al., editors. Harrison’s Principles of Internal Medicine, 18th ed. Boston: McGraw-Hill Medical; 2011. p. 341–359.
81.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–72.PubMedCrossRef
82.
Mori T, Katayama Y, Kawamata T, Hirayama T. Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1999;91(6):947–52.PubMedCrossRef
83.
Wijdicks EF, Vermeulen M, van Brummelen P, van Gijn J. The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1988;90(3):209–14.PubMedCrossRef
84.
Woo MH, Kale-Pradhan PB. Fludrocortisone in the treatment of subarachnoid hemorrhage-induced hyponatremia. Ann Pharmacother. 1997;31(5):637–9.PubMed
85.
Katayama Y, Haraoka J, Hirabayashi H, et al. A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2373–5.PubMedCrossRef
86.
Moro N, Katayama Y, Kojima J, Mori T, Kawamata T. Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage. Stroke. 2003;34(12):2807–11.PubMedCrossRef
87.
Ogden AT, Mayer SA, Connolly ES Jr. Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline. Neurosurgery. 2005;57(2):207–15.PubMedCrossRef
88.
Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med. 1997;126(1):20–5.PubMedCrossRef
89.
Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol. 2011;7:151–61.PubMedCrossRef
90.
Porzio P, Halberthal M, Bohn D, Halperin ML. Treatment of acute hyponatremia: ensuring the excretion of a predictable amount of electrolyte-free water. Crit Care Med. 2000;28(6):1905–10.PubMedCrossRef
91.
92.
Torres AC, Wickham EP, Biskobing DM. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose. Endocr Pract. 2011;17(4):e97–100.PubMedCrossRef
93.
Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–12.PubMedCrossRef
94.
Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112.PubMedCrossRef
95.
Graziani G, Cucchiari D, Aroldi A, et al. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug. J Neurol Neurosurg Psychiatry. 2012;83(5):510–2.PubMedCrossRef
96.
Potts MB, DeGiacomo AF, Deragopian L, Blevins LS Jr. Use of Intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion. Neurosurgery. 2011;69:268–73.PubMedCrossRef
97.
Schrier RW, Masoumi A, Elhassan E. Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome. Blood Purif. 2009;27(1):28–32.PubMedCrossRef
98.
Fraser JF, Stieg PE. Hyponatremia in the neurosurgical patient: epidemiology, pathophysiology, diagnosis, and management. Neurosurgery. 2006;59(2):222–9; discussion 222–9.PubMedCrossRef
99.
Braley LM, Adler GK, Mortensen RM, et al. Dose effect of adrenocorticotropin on aldosterone and cortisol biosynthesis in cultured bovine adrenal glomerulosa cells: in vitro correlate of hyperreninemic hypoaldosteronism. Endocrinology. 1992;131(1):187–94.PubMedCrossRef
100.
Zhang Y, Mircheff AK, Hensley CB, et al. Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresis. Am J Physiol. 1996;270(6 Pt 2):F1004–14.PubMed
Metadaten
Titel
Hyponatremia and Brain Injury: Historical and Contemporary Perspectives
verfasst von
Matthew A. Kirkman
Angelique F. Albert
Ahmed Ibrahim
Doris Doberenz
Publikationsdatum
01.06.2013
Verlag
Humana Press Inc
Erschienen in
Neurocritical Care / Ausgabe 3/2013
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-012-9805-y

Weitere Artikel der Ausgabe 3/2013

Neurocritical Care 3/2013 Zur Ausgabe

ORIGINAL ARTICLE

Bivalirudin as a Bridge for Anticoagulation in High Risk Neurosurgical Patients with Active DVT or High Risk of Thrombosis

ORIGINAL ARTICLE

The Effect of a Neurocritical Care Service without a Dedicated Neuro-ICU on Quality of Care in Intracerebral Hemorrhage

Editorial

What Keeps Patients with Subarachnoid Hemorrhage in the Neurosciences ICU?

Brief Communication

Perimesencephalic Subarachnoid Hemorrhage Triggered by Hypoxic Training During Swimming

Practical Pearl

Bedside Lung Ultrasound: A Case of Neurogenic Pulmonary Edema

Original Article

Intra-hospital Transport of Brain-Injured Patients: A Prospective, Observational Study

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise